
Differentiating Oncology Research Pipeline In Today’s Competitive Era
Clinical Leader | August 2019
Big pharma is increasingly doubling down on bets to develop new blockbuster cancer drugs. Currently, approximately 700 organizations have one or more oncology drugs in late-stage development, and 14 of the world’s largest pharmaceutical companies are focusing at least one-third of their late-stage R&D activity on oncology.
Read more ›